What is a stock summary page? Click here for an overview.
Business Description
Evolus Inc
NAICS : 325411
SIC : 2833
ISIN : US30052C1071
Compare
Compare
Traded in other countries / regions
EOLS.USA0K16.UKEVL.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2018-02-08Description
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.71 | |||||
| Equity-to-Asset | 0.02 | |||||
| Debt-to-Equity | 22.32 | |||||
| Debt-to-EBITDA | -4.76 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -0.71 | |||||
| Beneish M-Score | -2.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 28.9 | |||||
| 3-Year EBITDA Growth Rate | 16.2 | |||||
| 3-Year EPS without NRI Growth Rate | 14.6 | |||||
| 3-Year FCF Growth Rate | 18.9 | |||||
| 3-Year Book Growth Rate | -61.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 30.58 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.86 | |||||
| 9-Day RSI | 18.47 | |||||
| 14-Day RSI | 26.32 | |||||
| 3-1 Month Momentum % | 24.46 | |||||
| 6-1 Month Momentum % | -12.18 | |||||
| 12-1 Month Momentum % | 6.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | |||||
| Quick Ratio | 2.21 | |||||
| Cash Ratio | 1.38 | |||||
| Days Inventory | 56.28 | |||||
| Days Sales Outstanding | 54.9 | |||||
| Days Payable | 43.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.5 | |||||
| Shareholder Yield % | -11.48 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.33 | |||||
| Operating Margin % | -10.23 | |||||
| Net Margin % | -18.94 | |||||
| FCF Margin % | -8.57 | |||||
| ROE % | -885.18 | |||||
| ROA % | -22.69 | |||||
| ROIC % | -29.02 | |||||
| 3-Year ROIIC % | 468.08 | |||||
| ROC (Joel Greenblatt) % | -206.06 | |||||
| ROCE % | -18.51 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 538.93 | |||||
| PS Ratio | 2.38 | |||||
| PB Ratio | 113.78 | |||||
| EV-to-EBIT | -23.34 | |||||
| EV-to-Forward-EBIT | -39.84 | |||||
| EV-to-EBITDA | -27.95 | |||||
| EV-to-Forward-EBITDA | -54.55 | |||||
| EV-to-Revenue | 2.72 | |||||
| EV-to-Forward-Revenue | 2.05 | |||||
| EV-to-FCF | -31.67 | |||||
| Price-to-GF-Value | 0.64 | |||||
| Earnings Yield (Greenblatt) % | -4.28 | |||||
| FCF Yield % | -3.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EOLS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evolus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 266.274 | ||
| EPS (TTM) ($) | -0.81 | ||
| Beta | 1.44 | ||
| 3-Year Sharpe Ratio | 0.24 | ||
| 3-Year Sortino Ratio | 0.41 | ||
| Volatility % | 59.73 | ||
| 14-Day RSI | 26.32 | ||
| 14-Day ATR ($) | 0.738874 | ||
| 20-Day SMA ($) | 12.603 | ||
| 12-1 Month Momentum % | 6.93 | ||
| 52-Week Range ($) | 9.25 - 17.82 | ||
| Shares Outstanding (Mil) | 63.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evolus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evolus Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Evolus Inc Frequently Asked Questions
What is Evolus Inc(EOLS)'s stock price today?
The current price of EOLS is $10.24. The 52 week high of EOLS is $17.82 and 52 week low is $9.25.
When is next earnings date of Evolus Inc(EOLS)?
The next earnings date of Evolus Inc(EOLS) is 2025-05-07 Est..
Does Evolus Inc(EOLS) pay dividends? If so, how much?
Evolus Inc(EOLS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers